Top Companies in Nanomedicine Market | Industry Top Key Players In-depth Comprehensive Report by Vantage Market Research
Nanomedicine is the use of nanotechnology in the diagnosis and treatment of diseases.
Coralia.Joe
MARKET OVERVIEW
The Global Nanomedicine Market is valued at USD 173.1 Billion in the year 2021 and is expected to reach a value of USD 288.7 Billion by the year 2028. The Global Market is anticipated to grow to exhibit a Compound Annual Growth Rate (CAGR) of 8.9% over the forecast period. Nanomedicine is a technology that implements nanotechnology in the clinical discipline taking benefit of the abnormal homes of Nano scale materials. Nanomedicine may be divided into nanoparticles, Nano-shells, nanotubes, and Nanodevices.
Nanomedicine has utility in drug transport, biomaterials, lively implants, diagnostic imaging, regenerative remedy, and vaccines amongst others. Nanotechnology gives numerous advantages together with target-orientated and site-unique transport of specific medicines. Utilization of various forms of nanoparticles in the improvement of novel transport merchandise will gasoline the Nanomedicine enterprise increase. Biopharmaceutical and medical devices companies are actively engaged in the improvement of novel products as established with the aid of using the more and more developing partnerships among main enterprises and Nanomedicine startups. This strategic partnership is predicted to upward thrust the internet annual income of the products uplifting the market growth.
Get Access to Our Free Sample Report: https://www.vantagemarketresearch.com/nanomedicine-market-1632/request-sample
Some of the key players operating in the Nanomedicine Market are listed below:
|
Company Name |
Revenue in the US |
|
$43 Billion |
|
$12 Million |
|
<$5 Million |
|
<$5 Million |
|
<$5 Million |
|
<$5 Million |
|
$18 Billion |
|
$93 Billion |
|
$2 Billion |
|
$52 Billion |
Abbott Laboratories (Abbott) discovers, develops, manufactures and sells a diversified range of healthcare products including branded generic pharmaceuticals, diagnostic systems and tests, and pediatric and adult nutritional products. The company also offers various medical devices including heart failure, electrophysiology, rhythm management, vascular and structural heart devices, and neuromodulator devices. The company also offers minerals and nutrition products and various dietary supplements. It has research and development facilities in the US, China, Colombia, India, Singapore, Spain, and the UK; and operates manufacturing facilities across the world. The company markets products in North America, Latin America, the Middle East, Europe, Asia-Pacific, and Africa. Abbott is headquartered in Abbott Park, Illinois, the US.
CombiMatrix works to untangle the complicated matrix of genetic profiles. The company develops and sells diagnostic testing supplies and provides related laboratory services. Through its CombiMatrix Molecular Diagnostics subsidiary, it provides molecular diagnostic testing assays and other genetic analysis products. The company's focus lies in pre-implantation genetic diagnostics and screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders through offering DNA-based testing, including single nucleotide polymorphism chromosomal microarray analysis, next-generation sequencing, fluorescent in situ hybridization, and high-resolution karyotyping, enabling physicians to detect genetic abnormalities beyond what can be identified through traditional methodologies.
Clene Inc. is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements). The Company focuses on the development of unique therapeutics for neurodegenerative diseases. Clene provides a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Cline has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic with an aqueous solution of ionic zinc and ionic silver for anti-viral and anti-microbial uses.
Cellics Therapeutics, Inc. (Cellics) was founded by UC San Diego Professor Liang Fang Zhang based on his award-winning Cellular Nanoparticle (CNP) Technology. Cellics was created with the goal of applying CNP Technology to treat and prevent diseases. The mission of Cellics is to employ innovative biomimetic Nanomedicines to address serious diseases with a high unmet medical needs. The company’s initial primary focus is on autoimmune and inflammatory diseases and hard-to-treat infectious diseases. Additionally, Cellics is seeking to develop best-in-class vaccines for various diseases. The company has received IND allowance for its lead drug product CTI-005 for patients hospitalized with methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-sensitive Staphylococcus aureus (MSSA) pneumonia. With the IND allowance, the company plans to start the clinical trial, which will be a multicenter, randomized, double-blind, placebo-controlled Phase 1b/2a trial investigating the safety and potential efficacy of CTI-005 in MRSA and MSSA pneumonia patients. It is the passion and goal of Cellics to use advanced technology to help human beings live healthier and longer lives.
Nanobiotix SA is a clinical-stage biotechnology company that focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The Company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy.
Celgene Corp (Celgene), a subsidiary of Bristol-Myers Squibb Co, is an integrated biopharmaceutical company that discovers, develops, manufactures, and markets novel gene and protein regulation therapies for the treatment of cancer and immune-inflammatory diseases. Its major product portfolio includes Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide) for the treatment of multiple myeloma; and Abraxane (paclitaxel albumin-bound particles for injectable suspension) for various types of cancers, among others. The company sells its products through own sales organizations and distributors in Europe, the Americas, the Middle East and Asia-Pacific. Celgene is headquartered in Summit, New Jersey, the US.
GE Healthcare is a provider of transformational medical technologies and services. It specializes in medical imaging, information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, computerized data management, performance improvement, and medical equipment and performance services. The company was founded in 1892 and is headquartered in Chicago, Illinois. It follows an aggressive acquisition strategy and focuses on partnering with healthcare leaders trying to enhance the company's foothold in emerging markets and also broaden its life sciences portfolio. The Company offers scanners, monitors, dispensers, imagers, displays, recorders, analyzers, separators, and other laboratory and medical equipment for medical and medical research industries worldwide.
Johnson & Johnson is a holding company, which engages in the research and development, manufacture, and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
Mallinckrodt Plc. engages in the development, manufacture, market, and distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes innovative specialty pharmaceutical brands. The Specialty Generics segment relates to niche specialty generic drugs and active pharmaceutical ingredients. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt, and Edward Mallinckrodt in 1867 and is headquartered in Blanchard town, Dublin.
The company is known as Merck in the U.S. and Canada. Everywhere else, are known as MSD. Merck & Co., Inc. is the legal name and is listed on the New York Stock Exchange under the symbol “MRK.” Merck, known as MSD outside of the United States and Canada, is unified around the purpose: The use of the power of leading-edge science to save and improve lives around the world. It aspires to be the premier research-intensive biopharmaceutical company in the world – and today, at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. The diverse and inclusive global workforce operates responsibly every day to enable a safe, sustainable, and healthy future for all people and communities.
Read Latest Blog Top Companies in Microelectronics Market: https://v-mr.biz/microelectronics-market
Do You Have Any Query or Specific Requirements? You may enquire to our sales team before purchase.
Contact us
Eric Kunz
6218 Georgia Avenue NW Ste 1 - 564
Washington DC 20011-5125
United States Tel: +1 202 380 9727
Email: [email protected]
Website: https://www.vantagemarketresearch.com/
Follow Us on LinkedIn: https://www.linkedin.com/company/vantage-market-research/
Follow Us on Twitter: https://twitter.com/vantagemarketr
